論文 - 佐治 重衡
-
Advancing equitable access to innovation in breast cancer
O'Reilly S, Luis IV, Adam V, Razis ED, Urruticoechea A, Arahmani A, Carrasco E, Chua BH, Bliss J, Straehle C, Goulioti T, Lindholm B, Werustsky G, Brain E, Bedard PL, Curigliano G, Loi S, Saji S, Cameron D
NPJ Breast Cancer 11 ( 1 ) 71 2025年7月
-
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
Yoshinami T, Takano Y, Ozaki Y, Kajiwara Y, Yamamoto M, Watanabe KI, Tsukabe M, Fujisawa F, Nagai SE, Shibata N, Oshiro C, Bando H, Tsunoda N, Yamagami K, Koizumi K, Takada M, Toriguchi N, Sekine N, Kawaguchi T, Saji S, Sagara Y, Morita S, Masuda N.
Breast Cancer 32 ( 4 ) 841 - 856 2025年7月
-
Annual report of National Clinical Database-Breast Cancer Registry in 2021: characteristics categorized by body mass index and menopause status(タイトル和訳中)
Konishi Takaaki, Kumamaru Hiraku, Niikura Naoki, Sagara Yasuaki, Miyashita Minoru, Iwamoto Takayuki, Sanuki Naoko, Tanakura Kenta, Nagahashi Masayuki, Yoshida Masayuki, Kawashima Masahiro, Kinoshita Takayuki, Sasada Shinsuke, Kinukawa Naoko, Saji Shigehira, Ishida Takanori, Taira Naruto
Breast Cancer 32 ( 4 ) 621 - 629 2025年7月（ ISSN:1340-6868 ）
-
Konishi T, Kumamaru H, Niikura N, Sagara Y, Miyashita M, Iwamoto T, Sanuki N, Tanakura K, Nagahashi M, Yoshida M, Kawashima M, Kinoshita T, Sasada S, Kinukawa N, Saji S, Ishida T, Taira N
Breast cancer (Tokyo, Japan) 32 ( 4 ) 621 - 629 2025年7月（ ISSN:1340-6868 ）
-
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial
15. Mittendorf EA, Assaf ZJ, Harbeck N, Zhang H, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Qamra A, Dieterich M, Xu Y, Liste-Hermoso M, Shearer-Kang E, Molinero L, Chui SY, Barrios CH
Nat Med 31 ( 7 ) 2397 - 2404 2025年7月
-
Taji T, Kumamaru H, Kataoka Y, Iijima K, Suwa H, Ishiguro H, Taira N, Ishida T, Saji S
Breast (Edinburgh, Scotland) 81 104460 2025年6月（ ISSN:0960-9776 ）
-
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis
5. Yamamoto Y, Iwata H, Saji S, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Taira N, Morita S, Toi M, Ohno S, Masuda N.
J Clin Oncol. 43 ( 14 ) 1631 - 1637 2025年5月
-
Treatment patterns and clinical outcomes in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer treated with chemotherapy: a large-scale data analysis using the Japanese claims database
Kimura T, Takami T, Piao Y, Wang M, Saji S
Breast Cancer Res Treat 211 ( 1 ) 233 - 244 2025年5月
-
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
21. Schmid P, Oliveira M, O'Shaughnessy J, Cristofanilli M, Graff SL, Im SA, Loi S, Saji S, Wang S, Cescon DW, Hovey T, Nawrot A, Tse K, Vukovic P, Curigliano G.
Ther Adv Med Oncol 17 1758835925 2025年4月
-
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
Yamashita T, Saji S, Takano T, Naito Y, Tsuneizumi M, Yoshimura A, Takahashi M, Tsurutani J, Iwatani T, Kitada M, Tada H, Mori N, Higuchi T, Iwasa T, Araki K, Koizumi K, Hasegawa H, Uchida Y, Morita S, Masuda N.
J Clin Oncol. 43 ( 11 ) 1302 - 1313 2025年4月
-
2022年の日本の乳癌統計 全国がん登録データベース乳癌登録の年次報告 エストロゲン受容体低発現乳癌の化学療法感受性を含む臨床的意義(Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression)
Nagahashi Masayuki, Kumamaru Hiraku, Kinukawa Naoko, Iwamoto Takayuki, Kawashima Masahiro, Kinoshita Takayuki, Konishi Takaaki, Sagara Yasuaki, Sasada Shinsuke, Saji Shigehira, Sanuki Naoko, Tanakura Kenta, Niikura Naoki, Miyashita Minoru, Yoshida Masayuki, Ishida Takanori, Taira Naruto
Breast Cancer 32 ( 2 ) 217 - 226 2025年3月（ ISSN:1340-6868 ）
-
Nagahashi M, Kumamaru H, Kinukawa N, Iwamoto T, Kawashima M, Kinoshita T, Konishi T, Sagara Y, Sasada S, Saji S, Sanuki N, Tanakura K, Niikura N, Miyashita M, Yoshida M, Ishida T, Taira N
Breast cancer (Tokyo, Japan) 32 ( 2 ) 217 - 226 2025年3月（ ISSN:1340-6868 ）
-
Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy.
Ito M, Amari M, Sato A, Hikichi M, Tsurumi N, Otofuji H, Saji S.
Breast Cancer Res Treat. 209 ( 3 ) 503 - 512 2025年2月
-
Merging of the Fukushima Health Management Survey With the National and Local Cancer Registry to Refine the Detection of Thyroid Cancer Cases After the 2011 Fukushima Daiichi Nuclear Power Plant Accident
Kimura-Tsuchiya R, Nagao M, Saji S, Hayashi F, Ohira T, Shimura H, Furuya F, Suzuki S, Suzuki S, Ishikawa T, Yokoya S, Ohto H, Yasumura S.
Cancer Med 14 ( 3 ) e70610 2025年2月
-
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B; TROPION-Breast01 Investigators.
J Clin Oncol. 43 ( 3 ) 285 - 296 2025年1月
-
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial
Ignatiadis M, Bailey A, McArthur H, El-Abed S, de Azambuja E, Metzger O, Chui SY, Dieterich M, Perretti T, Shearer-Kang E, Molinero L, Steger GG, Jassem J, Lee SC, Higgins M, Zarba J, Schmidt M, Gomez H, Guerrero Zotano A, Moscetti L, Chiu J, Munzone E, Ben-Baruch NE, Bajetta E, Ohno S, Im SA, Werutsky G, Gal-Yam EN, Gonzalez Farre X, Tseng LM, Jacot W, Gluz O, Shao Z, Shparyk Y, Zimina A, Winer E, Cameron DA, Viale G, Saji S, Gelber R, Piccart M.
JAMA 333 ( 13 ) 1150 - 1160 2025年1月
-
Effect of Combined Exercise and Nutrition Interventions During Inpatient Chemotherapy in Acute Leukemia and Malignant Lymphoma Patients: A Randomized Controlled Trial.
Kasahara R, Morishita S, Fujita T, Jinbo R, Kubota J, Takano A, Takahashi S, Kisara S, Jinbo K, Yamamoto Y, Kakuta M, Kai T, Shiga Y, Kimura H, Furukawa M, Saji S
Nutrition and cancer 77 ( 1 ) 115 - 123 2025年
-
Development of cancer therapy-related cardiac dysfunction in anthracycline-treated breast cancer patients: a retrospective study.
Kuroda J, Oikawa M, Tokuda E, Tachibana K, Sasaki E, Ohtake T, Takeishi Y, Saji S.
Support Care Cancer. 33 ( 1 ) 8 2024年12月
-
Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial).
Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Kobayashi T, Katagiri Y, Kitada M, Tomioka N, Miyoshi Y, Shigematsu H, Miyashita M, Ishiguro H, Masuda N, Saji S.
Breast Cancer Res Treat. 208 ( 2 ) 253 - 262 2024年11月
-
Usefulness of urine dipstick test in the management of adverse events associated with immune checkpoint inhibitors.
Izumi K, Iyoda T, Yokota A, Kanno M, Hoshi M, Tokuda E, Sasaki E, Kanazawa K, Kuroda J, Saji S.
Support Care Cancer. 32 ( 11 ) 735 2024年10月